About Larova
Larova is a company based in Teltow (Germany) founded in 2003 by Mathias Gruen. It operates as a B2B and OEM. Larova offers products and services including dNTPs and rNTPs. Larova operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter Teltow, Germany
- Founders Mathias Gruen
- SectorsHealthcare
- Website larova.com
- Social LinkedIn X
- Legal Name Larova Gmbh
Products & Services of Larova
Larova offers a comprehensive portfolio of products and services, including dNTPs and rNTPs.
Deoxyribonucleotide triphosphates for PCR research applications
Ribonucleotide triphosphates for diagnostic uses
People of Larova
1 people are tracked at Larova (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mathias Gruen | Founder, MD | Leadership |
Complete people profiles for Larova
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Larova
Larova operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | – | RNA-sequencing transcriptome kits for health data analysis are developed. | |
| biofidelity.com | 2002 | Cambridge, United Kingdom | $59.91M | 28 | Molecular diagnostic assays are developed for target DNA sequence detection. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems | |
| sebia.com | 1967 | Evry Courcouronnes, France | – | – | Electrophoresis-based in vitro diagnostics products are developed and provided. | |
| nuprobe.com | 2016 | George Town, Cayman Islands | $61M | – | Sensitive multiplex platforms for QPCR are developed using toehold probes. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing |
Detailed competitors of Larova
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Larova
The website of Larova (larova.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 51.3% vs previous month
Websites whose visitors overlap most with Larova. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| swiftbiosci.com | 98% | – | – | View details | |
| upstate.com | 96% | – | – | View details | |
| usbio.com | 90% | – | – | View details | |
| polyplus-transfection.com | 87% | – | – | View details | |
| bioke.com | 71% | 15.2K | #1,729,834 | View details |
Similar companies to Larova
10 companies that operate in the same segment as Larova (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Larova
Larova was founded in 2003.
Larova is headquartered in Teltow, Germany. It is registered at Teltow, Brandenburg, Germany.
Larova is an original manufacturer of ultra-pure dNTPs and rNTPs, produced in Germany with capacities over 5000 liters annually. They operate under ISO 9001 certification, focusing on quality and environmental management. Based in Jena, Germany, the company supplies custom formulations and OEM services to reagent manufacturers, resellers, and laboratories globally for diagnostic and research applications.
Larova's top competitors include Neogen, Qiagen and Parse Biosciences.
Larova offers dNTPs and rNTPs.
Larova operates through Larova Gmbh.